These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 31611354)

  • 1. Intracellular Pharmacodynamic Modeling Is Predictive of the Clinical Activity of Fluoroquinolones against Tuberculosis.
    Donnellan S; Aljayyoussi G; Moyo E; Ardrey A; Martinez-Rodriguez C; Ward SA; Biagini GA
    Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31611354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluoroquinolones in Drug-Resistant Tuberculosis: Culture Conversion and Pharmacokinetic/Pharmacodynamic Target Attainment To Guide Dose Selection.
    Al-Shaer MH; Alghamdi WA; Alsultan A; An G; Ahmed S; Alkabab Y; Banu S; Barbakadze K; Houpt E; Kipiani M; Mikiashvili L; Cegielski JP; Kempker RR; Heysell SK; Peloquin CA
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31061152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting the Outcomes of New Short-Course Regimens for Multidrug-Resistant Tuberculosis Using Intrahost and Pharmacokinetic-Pharmacodynamic Modeling.
    Doan TN; Cao P; Emeto TI; McCaw JM; McBryde ES
    Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30249697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluoroquinolones for the treatment of pulmonary tuberculosis.
    Moadebi S; Harder CK; Fitzgerald MJ; Elwood KR; Marra F
    Drugs; 2007; 67(14):2077-99. PubMed ID: 17883288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Moxifloxacin population pharmacokinetics and model-based comparison of efficacy between moxifloxacin and ofloxacin in African patients.
    Zvada SP; Denti P; Sirgel FA; Chigutsa E; Hatherill M; Charalambous S; Mungofa S; Wiesner L; Simonsson US; Jindani A; Harrison T; McIlleron HM
    Antimicrob Agents Chemother; 2014; 58(1):503-10. PubMed ID: 24189253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluoroquinolones, the cornerstone of treatment of drug-resistant tuberculosis: a pharmacokinetic and pharmacodynamic approach.
    Pranger AD; Alffenaar JW; Aarnoutse RE
    Curr Pharm Des; 2011; 17(27):2900-30. PubMed ID: 21834759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Measurement of the Intracellular Mycobacterium tuberculosis Drug Effect and Prediction of the Clinical Dose-Response Relationship Using Intracellular Pharmacodynamic Modeling (PD
    Donnellan S; Martínez-Rodríguez C; Aljayyoussi G; Biagini GA
    Methods Mol Biol; 2021; 2296():393-408. PubMed ID: 33977461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma drug activity in patients on treatment for multidrug-resistant tuberculosis.
    Mpagama SG; Ndusilo N; Stroup S; Kumburu H; Peloquin CA; Gratz J; Houpt ER; Kibiki GS; Heysell SK
    Antimicrob Agents Chemother; 2014; 58(2):782-8. PubMed ID: 24247125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic-Pharmacodynamic modelling of intracellular Mycobacterium tuberculosis growth and kill rates is predictive of clinical treatment duration.
    Aljayyoussi G; Jenkins VA; Sharma R; Ardrey A; Donnellan S; Ward SA; Biagini GA
    Sci Rep; 2017 Mar; 7(1):502. PubMed ID: 28356552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluoroquinolone-resistant Mycobacterium tuberculosis, Pakistan, 2005-2009.
    Jabeen K; Shakoor S; Chishti S; Ayaz A; Hasan R
    Emerg Infect Dis; 2011 Mar; 17(3):564-6. PubMed ID: 21392465
    [No Abstract]   [Full Text] [Related]  

  • 11. Human Tuberculosis. III. Current and Prospective Approaches in Anti-Tubercular Therapy.
    Sgaragli G; Frosini M; Saponara S; Corelli F
    Curr Med Chem; 2016; 23(21):2245-74. PubMed ID: 27142291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparing efficacies of moxifloxacin, levofloxacin and gatifloxacin in tuberculosis granulomas using a multi-scale systems pharmacology approach.
    Pienaar E; Sarathy J; Prideaux B; Dietzold J; Dartois V; Kirschner DE; Linderman JJ
    PLoS Comput Biol; 2017 Aug; 13(8):e1005650. PubMed ID: 28817561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pyrazinamide may improve fluoroquinolone-based treatment of multidrug-resistant tuberculosis.
    Chang KC; Leung CC; Yew WW; Leung EC; Leung WM; Tam CM; Zhang Y
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5465-75. PubMed ID: 22869570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current prospects for the fluoroquinolones as first-line tuberculosis therapy.
    Takiff H; Guerrero E
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5421-9. PubMed ID: 21876059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Respiratory fluoroquinolones and pulmonary tuberculosis treatment when the main drugs are ineffective].
    Lazareva NB; Khaĭmenova TIu; Khaĭmenov AIa
    Antibiot Khimioter; 2008; 53(5-6):14-20. PubMed ID: 19069177
    [No Abstract]   [Full Text] [Related]  

  • 16. The role of moxifloxacin in tuberculosis therapy.
    Gillespie SH
    Eur Respir Rev; 2016 Mar; 25(139):19-28. PubMed ID: 26929417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Present and future in the use of anti-tubercular drugs].
    Didilescu C; Craiova UM
    Pneumologia; 2011; 60(4):198-201. PubMed ID: 22420168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluoroquinolones for the treatment of tuberculosis in children.
    Thee S; Garcia-Prats AJ; Donald PR; Hesseling AC; Schaaf HS
    Tuberculosis (Edinb); 2015 May; 95(3):229-45. PubMed ID: 25797610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluoroquinolone Efficacy against Tuberculosis Is Driven by Penetration into Lesions and Activity against Resident Bacterial Populations.
    Sarathy J; Blanc L; Alvarez-Cabrera N; O'Brien P; Dias-Freedman I; Mina M; Zimmerman M; Kaya F; Ho Liang HP; Prideaux B; Dietzold J; Salgame P; Savic RM; Linderman J; Kirschner D; Pienaar E; Dartois V
    Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30803965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Moxifloxacin plus standard first-line therapy in the treatment of pulmonary tuberculosis: A meta-analysis.
    Chen Z; Liang JQ; Wang JH; Feng SS; Zhang GY
    Tuberculosis (Edinb); 2015 Jul; 95(4):490-6. PubMed ID: 25964137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.